<DOC>
	<DOCNO>NCT02273648</DOCNO>
	<brief_summary>For majority Coronary Artery Disease ( CAD ) treatment Percutaneous Transluminal Coronary Angioplasty ( PTCA ) provide high initial procedure success . However , medium long-term complication range rather immediate elastic coil vessel contraction longer process like smooth muscle cell proliferation excessive production extra cellular matrix , thrombus formation atherosclerotic change like restenosis angiographic re-narrowing . The reported incidence restenosis PTCA range 30 50 % . Such rate recurrence serious economic consequence . Bare Metal Stents ( BMS ) , design address limitation PTCA , reduce angiographic clinical restenosis rate De Novo lesion compare PTCA alone decrease need CABG . BMS substantially reduce incidence abrupt artery closure , restenosis still occur 20 40 % case , necessitate repeat procedure . The invention Drug Eluting Stents ( DES ) significantly improve principle BMS add antiproliferative drug ( directly immobilize stent surface release polymer matrix ) , inhibit neointimal hyperplasia . The introduction DES greatly reduce incidence restenosis result good safety profile compare BMS systemic drug administration . These advantage low cost compare surgical intervention make DES attractive option treat coronary artery disease . Therefore observational registry design clinical evaluation ORSIRO LESS require coronary revascularization DES . It design investigate collect clinical evidence clinical performance safety Orsiro Drug Eluting Stent System all-comers patient population daily clinical practice .</brief_summary>
	<brief_title>BIOTRONIK - SaFety Performance Registry All-comers Patient Population With Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Symptomatic coronary artery disease Subject sign informed consent data release Subject geographically stable willing participate follow assessment Subject â‰¥ 18 year age Subject sign inform consent data release Pregnancy Known intolerance aspirin , clopidogrel , ticlopidine , heparin anticoagulation / antiplatelet therapy require PCI , stainless steel , Sirolimus contrast medium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>national</keyword>
	<keyword>multicenter</keyword>
	<keyword>observational registry</keyword>
	<keyword>Orsiro Drug Eluting Stent</keyword>
	<keyword>Stenting Treatment coronary artery disease</keyword>
	<keyword>coronary revascularization</keyword>
	<keyword>PCI</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Angina</keyword>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Small Vessels</keyword>
	<keyword>Chronic Total Occlusion</keyword>
</DOC>